Naltrexone Depot Formulations for Opioid and Alcohol Dependence: A Systematic Review
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
SUMMARY: Naltrexone is an opioid receptor antagonist that blocks the reinforcing effects of opioids and reduces alcohol consumption and craving. It has no abuse potential, mild and transient side effects, and thus appears an ideal pharmacotherapy for opioid dependence. Its effectiveness in alcohol dependence is less evident, but compliance with naltrexone combined with psychosocial support has been repeatedly shown to improve drinking outcomes. Limited compliance with oral naltrexone treatment is a known drawback. Several naltrexone implant and injectable depot formulations are being investigated and provide naltrexone release for at least 1 month. Studies among opioid‐dependent patients indicate significant reductions in heroin use, but sample sizes are usually small. In alcohol dependence, two large multicenter trials report alcohol and craving reductions for naltrexone and placebo groups, indicating a significant but moderate effect. The pharmacokinetic profile of the injectable formulation indicates reliable naltrexone release over 1 month at therapeutic levels. Implant formulations releasing naltrexone up to 7 months are reported. Findings on safety and tolerability confirm the generally mild adverse effects described for naltrexone tablets. However, further research on therapeutic levels (i.e., opioid blocking) is warranted. The majority of naltrexone implants lacks approval for regular clinical use and larger longitudinal studies are needed. The available naltrexone depot formulations have the potential to significantly improve medication compliance in opioid and alcohol dependence. In certain circumstances, they may constitute a promising new treatment option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
The incentive sensitization theory of addiction: some current issues
Robinson, T. E., & Berridge, K. C. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0093 · Cited by 1,717 · cited 1×
“Repeated stimulation with psychoactive substances is followed by neuroadaptation that may lead to a decrease in liking and an increase in wanting [2].”
BackgroundOslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451 · cited 1×
“Genetic polymorphism in the μOR gene has been related to differential patient response to oral naltrexone treatment and a single transcription factor has been suggested to predict improved drinking outcomes [33,34].”
BackgroundAlteration of ethanol self-administration by naltrexone
Altshuler, H. L., Phillips, P. E., & Feinhandler, D. A. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90257-x · Cited by 397
Depot naltrexone: long-lasting antagonism of the effects of heroin in humans
Comer, S., Collins, E., Kleber, H., Nuwayser, E., Kerrigan, J., & Fischman, M. (2002) · Psychopharmacology · doi:10.1007/s002130100909 · Cited by 175
Hulse, G. K., Morris, N., Arnold-Reed, D., & Tait, R. J. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.130 · Cited by 135 · cited 3×
“Most adverse affects have been found to be transient and mild to moderate [35,37].”
BackgroundNaltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial
Kun⊘e, N., Lobmaier, P., Vederhus, J. K., Hjerkinn, B., Hegstad, S., Gossop, M., Kristensen, Ø., & Waal, H. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.055319 · Cited by 88 · cited 3×
“Although no incident has been reported, attempted self-removal cannot be ruled out as a possible cause of two ruptured implant sites [36].”
BackgroundSelf-citation
Cited by
The role of the opioid system in decision making and cognitive control: a review
van Steenbergen, H., Eikemo, M., & Leknes, S. (2019) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/s13415-019-00710-6 · Cited by 118
Risk Factors, Clinical Consequences, Prevention, and Treatment of Childhood Obesity
Shaban Mohamed, M. A., AbouKhatwa, M. M., Saifullah, A. A., Hareez Syahmi, M., Mosaad, M., Elrggal, M. E., Dehele, I. S., & Elnaem, M. H. (2022) · Children · doi:10.3390/children9121975 · Cited by 52
“Naltrexone is an opioid receptor antagonist that is FDA approved for managing opioid and alcohol dependence [103].”
BackgroundTreatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Metadata
- Authors
- Lobmaier, P. P., Kunøe, N., Gossop, M., & Waal, H.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2010-09-23
- Volume
- 17
- Issue
- 6
- Pages
- 629-636
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W1515337023
- Cited by
- 77
- References
- 9
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naltrexone Depot Formulations for Opioid and Alcohol Dependence: A Systematic Review. https://app.cochat.ai/papers/10.1111/j.1755-5949.2010.00194.x
- The paper
- Lobmaier, P. P., Kunøe, N., Gossop, M., & Waal, H. (2011). Naltrexone Depot Formulations for Opioid and Alcohol Dependence: A Systematic Review. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2010.00194.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.